Capricor Therapeutics (CAPR) Plans to Report Top-line Data from Duchenne Muscular Dystrophy Trial

Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness. It is caused by an absence of dystrophin, a protein that helps keep muscle cells intact.

Shares of Capricor Therapeutics, Inc. (Nasdaq:CAPR) climbed more than 15% in the extended session Monday after the company said that it plans to announce top-line data from a safety and exploratory efficacy analysis of six-month data from the randomized 12-month Phase I/II HOPE Clinical Trial evaluating its investigational candidate CAP-1002 (allogeneic cardiosphere-derived cells) in Duchenne muscular dystrophy patients.

The clinical-stage biotechnology company will host a conference call and webcast ( www.wsw.com/webcast/cc/capr ) with slides on Tuesday, April 25, 2017, at 8:00 a.m. Eastern Time to discuss the top-line clinical trial results.

Capricor Therapeutics is developing first-in-class biological therapies for cardiac and other medical conditions. Its lead candidate, CAP-1002, is a cell-based candidate currently in clinical development for the treatment of Duchenne muscular dystrophy, myocardial infarction (heart attack), and heart failure. The company is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

*

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer